Psychosis in advanced Parkinson's disease

@article{Zoldan1995PsychosisIA,
  title={Psychosis in advanced Parkinson's disease},
  author={J. Zoldan and G. Friedberg and M. Livneh and E. Melamed},
  journal={Neurology},
  year={1995},
  volume={45},
  pages={1305 - 1308}
}
  • J. Zoldan, G. Friedberg, +1 author E. Melamed
  • Published 1995
  • Medicine
  • Neurology
  • Psychosis, linked to chronic levodopa and other antiparkinsonian drug treatments, is a common and incapacitating complication of advanced Parkinson's disease (PD). The psychosis may be due, in part, to overstimulation of central serotonergic (5-HT) receptors. We treated 16 PD patients who had psychosis of 6 to 60 months' duration with the 5-HT3 receptor antagonist ondansetron (12 to 24 mg daily) in an open-label, short-term (4 to 8 weeks) trial. There was marked to moderate improvement (p < 0… CONTINUE READING
    166 Citations
    Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
    • 2
    • PDF
    Parkinson Disease Psychosis: Update
    • J. Friedman
    • Psychology, Medicine
    • Behavioural neurology
    • 2013
    • 66
    • PDF
    Pathophysiology and Treatment of Psychosis in Parkinson’s Disease
    • 123
    Psychosis in Parkinson’s Disease
    • 33
    • PDF
    Psychosis in Parkinson's disease: therapeutic options.
    • 13
    • PDF
    Evidence for the use of pimavanserin in the treatment of Parkinson’s disease psychosis
    • 9
    Mirtazapine improves visual hallucinations in Parkinson's disease: a case report
    • 25

    References

    SHOWING 1-10 OF 14 REFERENCES
    New antipsychotics: classification, efficacy, and adverse effects.
    • J. Gerlach
    • Psychology, Medicine
    • Schizophrenia bulletin
    • 1991
    • 176
    • PDF
    Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial.
    • 38
    NOSIE-30: A Treatment-Sensitive Ward Behavior Scale
    • 323
    factors for nursing home placement in advanced Parkinson's disease
    • Neurology
    • 1993
    The management of the 'levodopa psychosis
    • Clin Neuropharmacol
    • 1991
    5-HT3 receptor antagonists: an overview of their present status and future potential in cancer therapyinduced emesis
    • Drugs
    • 1990
    The Brief Psychiatric Rating Scale. Recent developments in ascertainment and scaling
    • Psychopharmacol Bull
    • 1988